Fintel reports that on January 31, 2025, Evercore ISI Group initiated coverage of NNN REIT (NYSE:NNN) with a In-Line ...

Fintel reports that on January 28, 2025, Evercore ISI Group initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a ...

Fintel reports that on January 31, 2025, Evercore ISI Group initiated coverage of NNN REIT (NYSE:NNN) with a In-Line recommendation. As of January 28, 2025, the average one-year price target for ...

In a report released yesterday, David Motemaden from Evercore ISI maintained a Buy rating on MSCI (MSCI – Research Report), with a price target ...

Evercore ISI analyst David Motemaden maintained a Sell rating on Renaissancere Holdings (RNR – Research Report) yesterday and set a price ...

Approached for comment, Atrium CEO John Fowle confirmed that the insurer was working with Evercore and Stone Point to explore “multiple options” around its capital structure. He said this formed part ...

BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor are acting as joint bookrunners for the offering. A registration statement on Form S-1 (File No. 333-284225 ...

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...

PASADENA, Calif., Jan. 30, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. ("Alexandria" or the "Company") (NYSE: ARE) today announced that it has priced a public offering of $ ...

Metsera, Inc., a clinical-stage biotechnology company specializing in obesity treatments through injectable and oral hormone analog peptides, announced the pricing of its initial public offering ...